JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Schrodinger Inc

Geschlossen

BrancheGesundheitswesen

11.81 3.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.72

Max

11.85

Schlüsselkennzahlen

By Trading Economics

Einkommen

169M

136M

Verkäufe

33M

87M

EPS

-0.18

Gewinnspanne

155.644

Angestellte

850

EBITDA

67M

36M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.79% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

118M

945M

Vorheriger Eröffnungskurs

8.39

Vorheriger Schlusskurs

11.81

Nachrichtenstimmung

By Acuity

46%

54%

136 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Schrodinger Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank -2-

24. Apr. 2026, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Group Rejects EQT's Revised Offer

26. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. Apr. 2026, 23:36 UTC

Market Talk
Wichtige Nachrichtenereignisse

Gold Falls Amid Dollar's Strength -- Market Talk

26. Apr. 2026, 23:33 UTC

Market Talk
Wichtige Nachrichtenereignisse

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. Apr. 2026, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Scoring the Cook Era -- Barrons.com

24. Apr. 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:50 UTC

Market Talk
Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:09 UTC

Ergebnisse

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. Apr. 2026, 19:48 UTC

Market Talk
Wichtige Nachrichtenereignisse

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. Apr. 2026, 19:22 UTC

Ergebnisse

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. Apr. 2026, 19:06 UTC

Ergebnisse

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. Apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. Apr. 2026, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. Apr. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Rejects Revised EQT Offer

24. Apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. Apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. Apr. 2026, 17:42 UTC

Ergebnisse

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Ergebnisse

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer-Vergleich

Kursveränderung

Schrodinger Inc Prognose

Kursziel

By TipRanks

54.79% Vorteil

12-Monats-Prognose

Durchschnitt 18.25 USD  54.79%

Hoch 20 USD

Tief 13 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Schrodinger Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

4

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

23.27 / 26.13Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Very Strong Bullish Evidence

Stimmung

By Acuity

136 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat